Dados B3 › AZTE3 × UGPA3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | AZTE3 | UGPA3 | year |
|---|---|---|---|
| ROE | 0.0% | 15.9% | 2025 |
| ROIC | -2.6%! | 12.1% | 2025 |
| ROA | -4.3% | 5.7% | 2025 |
| Gross margin | 59.1% | 6.6% | 2025 |
| EBIT margin | -278.0%! | 3.5% | 2025 |
| Net margin | -343.0% | 1.8% | 2025 |
| Net debt/EBITDA | — | 2.26x | no year where both have it |
| Current ratio | 0.61x | 1.62x | 2025 |
| Revenue growth (1y) | 30.7% | 6.6% | 2025 |
| Revenue growth (5y CAGR) | — | 14.0% | no year where both have it |
| Piotroski F-Score | 4/9 | 4/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | AZTE3 | UGPA3 | year |
|---|---|---|---|
| P/E | — | 11.46x | 2025 |
| P/B | 0.56x | 1.79x | 2025 |
| EV/EBITDA | — | 6.54x | 2025 |
| FCF yield | -74.5% | 12.3% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:53 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it